fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

FDA approves Zoryve (roflumilast) cream 0.3% for treatment of psoriasis in children ages 6 to 11- Arcutis Biotherapeutics

Written by | 15 Oct 2023

Arcutis Biotherapeutics, Inc. announced the FDA has approved the supplemental new drug application (sNDA) to expand the indication of Zoryve (roflumilast) cream 0.3% for the topical treatment of… read more.

Arcutis and Huadong announce strategic collaboration and licensing agreement for topical roflumilast in Greater China and Southeast Asia

Written by | 20 Aug 2023

Arcutis Biotherapeutics, Inc. and Hangzhou Zhongmei Huadong Pharmaceutical Co, a wholly owned subsidiary of Huadong Medicine Co., Ltd. (SZ.000963), announced that the companies have entered into a strategic… read more.

Bristol Myers Squibb launches Clear Understanding Campaign to reveal the plain truth about living with moderate to severe plaque psoriasis

Written by | 16 Aug 2023

Bristol Myers Squibb has launched Clear Understanding, a campaign featuring patients living with moderate to severe plaque psoriasis who are sharing what it’s really like for them to… read more.

Large study shows link between Vitamin D and psoriasis severity

Written by | 31 Jul 2023

More than eight million people in the U.S. experience psoriasis, a condition in which skin cells build up and form itchy dry patches. A person’s vitamin D levels… read more.

FDA action for BLA for bimekizumab for the treatment of adults with moderate to severe plaque psoriasis is now shifted to Q3 2023 – UCB

Written by | 10 Jul 2023

UCB, a global biopharmaceutical company,announced that the Biologics License Application (BLA) for bimekizumab for the treatment of adults with moderate to severe plaque psoriasis remains under review with… read more.

Study helps explain what drives psoriasis severity and offers clues as to how disease may spread to other body parts

Written by | 7 Jun 2023

Beneath and beyond the reddish, flaky lesions that form in the skin of those with psoriasis, mild and severe forms of the disease can be told apart by… read more.

Testing a immunological drug as a new treatment for early type 1 diabetes

Written by | 29 Jan 2023

A large clinical study is now beginning on an approved drug for treating psoriasis. The drug will be tested on patients who were recently diagnosed with type 1… read more.

Suffering from psoriasis? Blame this trio of proteins

Written by | 27 Nov 2021

New study shows there may be a way to help even more psoriasis patients. About 7.5 million Americans suffer from psoriasis, an autoimmune disease that shows up as… read more.

Safety analysis of biologics and highlighting vaccine hesitancy: real-world data shines a light on the impact of COVID-19 on psoriasis patients

Written by | 11 Oct 2021

Real-world data looking at biologic treatment and vaccine hesitancy in psoriasis patients is being presented at EADV’s 30th Congress. The findings of two studies are helping to advance… read more.

Novartis Cosentyx receives FDA approval for treatment of children and adolescents with moderate to severe plaque psoriasis

Written by | 8 Jun 2021

Novartis,has announced the FDA has approved Cosentyx (secukinumab) for the treatment of moderate to severe plaque psoriasis in pediatric patients six years and older who are candidates for… read more.

Otezla significantly improved measures of disease severity in adults with mild-to-moderate plaque psoriasis – Amgen

Written by | 29 Apr 2021

Amgen announced Otezla (apremilast) improved measures of disease severity in adults with mild-to-moderate plaque psoriasis regardless of their Body Surface Area (BSA) affected by the disease , according… read more.

Health Canada approves Taltz for pediatric patients with plaque psoriasis – Eli Lilly

Written by | 2 Apr 2021

Health Canada issued a Notice of Compliance for Taltz (ixekizumab), from Eli Lilly, injection, 80 mg/mL, for the treatment of pediatric patients from six to less than 18… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.